Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Mar
19
Today In Oncology
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
High Cancer Burden Shifted From Urban to Rural Areas
Study Finds No Overall Increase in Cancer Risk After Medically Assisted Reproduction
SMFM Issues New Clinical Guidance for Cancer Diagnosis and Treatment During Pregnancy
Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo